PharmaLive > Business

Featured Posts

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Ad-ventures in Marketing XI

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.

Mobile Marketing Special Feature Part 1: Growing voice for mobile

Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.

Mobile Marketing Special Feature Part 2: Getting pharma into new mobile tech

Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.

Mobile Marketing Special Feature Part 3: Still a case for apps

In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.

2018 Annual Report: Top 50 Companies – Looking to future challenges

The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.

Pharma Innovators Special Feature 2018: Focus on innovation

In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.

Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.

First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining

The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.

AR/VR Special Feature 2018: The new (augmented) reality in life sciences

Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.

AR/VR Special Feature 2018: Beyond the hype – AR and VR in healthcare

Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.

Payer Access Special Feature: Straining the system

Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.

Annual Report 2018: State of the Bio Industry

This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.

Consumer/Patient Experience Special Feature: Saving lives isn’t enough anymore

Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.

Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale

It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.

Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know

Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.

Agenda 2018 Special Feature: The song remains the same

The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.

Top 10 Pipelines 2018 Annual Report

Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.

Special Feature – Value of Medicines: The value equation

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

Israel’s Accelerated Evolution Biotechnologies Claims a Cure for Cancer

Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.

Tyson recalls chicken nuggets on possible rubber contamination

Tyson Foods Inc. is recalling some chicken nuggets the company manufactured because of possible contamination with rubber, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) said.

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc. reported fourth-quarter 2018 profit that easily surpassed expectations as sales rose and tax expense fell, but competition for the company’s older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

ASLAN, Aduro Initiate Corporate Restructuring That Includes Significant Layoffs

ASLAN Pharmaceuticals is cutting staff and initiating a corporate restructuring and strategic prioritization of the company’s clinical development programs. Aduro Biotech will institute a “strategic reset” to focus on the company’s core strengths of the discovery and development of novel product candidates in the stimulator of interferon genes and a proliferation-inducing ligand pathways.

Senate Finance Committee and House Oversight Committee Take Aim at Drug Pricing

The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.

EVERSANA unveils Health Strategies Insights

EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.

Novartis 2019 growth outlook leaves investors wanting more

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Neurocrine, Voyager team up on PD gene therapy

Shares of Voyager Therapeutics skyrocketed after the company announced a collaborative deal to develop a gene therapy treatment for Parkinson’s disease with Neurocrine Biosciences.

Botox maker Allergan’s 2018 revenue forecast misses estimates, shares drop

Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.

Pfizer forecasts 2019 revenue below Wall Street targets

Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.